Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

This was the stock's second consecutive day of losses.

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...

Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently disclosed in an 8-K filing with the Securities and Exchange Commission on January 13, 2025, that the company has posted a corporate presentation ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Catalyst Pharmaceuticals Inc. closed $2.08 short of its 52-week high ($24.27), which the company achieved on November 8th.

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes ...